About akronbiotech

Akron Biotech is an leading biotechnology company focused on discovery, development and manufacturing of advanced tools for regenerative medicine.

Akron participates in panel on human platelet lysate at AABB Annual Meeting

The 2017 Annual Meeting of the American Association of Blood Banks (AABB) took place from October 7 – 10, 2017 in San Diego, CA. Akron Biotechnology participated in a panel as part of the AABB/ISCT Joint Working Group, Pooled Human Platelet Lysate (pHPL) for Cell Therapies Manufacturing. The thrust for this meeting comes from the increasing prevalence and

Wearable textile bandage releases wound-healing drugs on demand

Multiple approaches have been described for achieving therapeutically-effective wound healing. Biological factors that induce stimulation of cells to trigger and enhance the healing process have been extensively studied, and recently, new approaches for their delivery have been the focus of a vast number of studies. Delivery issues inherent to wound dressings include the need to

Ancillary materials: now, more than ever, at the core of new cell therapies + Exclusive discount code for Phacilitate Cell & Gene therapy summit

Raw materials have been, and will continue to be, at the core of new sets of therapies coming out over the next decade. Why? Simply because they are either scarce or limited, such as off-the-clot AB serum, or because they encompass a high risk, which is the case for animal-derived components. For this type of materials, concerns

Vibrations replace media to induce differentiation of MSCs into bone tissue

Bone is the second most grafted tissue after blood – however, autologous grafts are in short supply and allogeneic grafts are associated with problems including rejection by the body and post-transplant complications. For that reason, much work has been put into optimizing existing and finding new ways for creating induced bone grafts through tissue engineering,

Reprogramming cells into induced pluripotent stem cells using antibodies one step closer

The reprogramming of differentiated stem cells into induced pluripotent stem cells (IPSCs) typically takes place via a set of transcription factors Oct4 (Pou5f1), Sox2, cMyc, and Klf4. While reprogramming can be induced by replacing these factors with miRNA, small molecules and alternative transcription factors, a new approach described a number of antibodies that can achieve reprogramming of mature stem cells. The work

Optogenetics: From injectable sensors to smartphone-controlled cells

First demonstrated in 2002, the principle of optogenetics has since been utilized to develop a variety of approaches for the light-actuated control of cell function, particularly in neuroscience research. The principle involves the engineering of cells to express a light-sensitive protein, typically an ion channel or a G protein-coupled receptor, followed by illumination with light

With CAR-T approval, FDA steps up efforts at regulating stem cell clinics

About two months and two weeks after the FDA’s advisory committe recommended for approval Novartis’ CAR-T therapy for the treatment of  relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL), the FDA followed up with an official approval. Tisagenlecleucel – or, as the therapy is commonly known, Kymriah – will head

Holoclar, Europe’s first stem cell therapy, receives UK approval recommendation

We first heard of Holoclar’s breakthrough success in 2015, when it received recommendation for approval by the European Medicines Agency. Holoclar, developed by Italian pharmaceutical company Chiesi Farmaceutici, is based on ex vivo expanded autologous human corneal epithelial cells, which contain limbal stem cells, and which repair the cornea after injury. Now, Holoclar has received another

From sterile filling to custom manufacturing: How Akron’s unique services and capabilities can work for you

Akron’s sterile manufacturing facility, presented here before, enables the unique preparation of products within a fully aseptic manufacturing environment, including sterile filtration and container-closure filling. And while this allows Akron to manufacture cGMP-compliant, sterile-filled cytokines and ancillary materials for cell therapy, Akron also extends these capabilities as services to serve the industry: Owing to our unique facilities, our manufacturing capabilities are among

Fibronectin and BMP act in synergy to improve osteogenic activity

Fibronectin is well-known as an attachment extracellular matrix (ECM) protein that promotes activity, including differentiation, of a number of cell types. It has also been used in a number of tissue engineered constructs to enhance their function as well as cellular proliferation. As a workhorse ECM protein, fibronectin’s use is well-established in many tissue engineering